Orzelska, J.; Trzcińska, A.; Gierulska, N.; Lachowska, K.; Mazur, K.; Tarkowski, R.; Puzio, I.; Tomaszewska, E.; Kułak, A.; Kułak, K.
Feasibility of Trastuzumab-Deruxtecan in the Treatment of Ovarian Cancer: A Systematic Review. J. Clin. Med. 2025, 14, 8483.
https://doi.org/10.3390/jcm14238483
AMA Style
Orzelska J, Trzcińska A, Gierulska N, Lachowska K, Mazur K, Tarkowski R, Puzio I, Tomaszewska E, Kułak A, Kułak K.
Feasibility of Trastuzumab-Deruxtecan in the Treatment of Ovarian Cancer: A Systematic Review. Journal of Clinical Medicine. 2025; 14(23):8483.
https://doi.org/10.3390/jcm14238483
Chicago/Turabian Style
Orzelska, Julia, Amelia Trzcińska, Natalia Gierulska, Katarzyna Lachowska, Karolina Mazur, Rafał Tarkowski, Iwona Puzio, Ewa Tomaszewska, Anna Kułak, and Krzysztof Kułak.
2025. "Feasibility of Trastuzumab-Deruxtecan in the Treatment of Ovarian Cancer: A Systematic Review" Journal of Clinical Medicine 14, no. 23: 8483.
https://doi.org/10.3390/jcm14238483
APA Style
Orzelska, J., Trzcińska, A., Gierulska, N., Lachowska, K., Mazur, K., Tarkowski, R., Puzio, I., Tomaszewska, E., Kułak, A., & Kułak, K.
(2025). Feasibility of Trastuzumab-Deruxtecan in the Treatment of Ovarian Cancer: A Systematic Review. Journal of Clinical Medicine, 14(23), 8483.
https://doi.org/10.3390/jcm14238483
